You are here

Newly Diagnosed? Would you like to participate in a Clinical Research Study of a new treatment for CML?

Have you recently been diagnosed with Chronic Myelogenous Leukaemia (CML)?

Was your diagnosis within the last 6 months?

Are you aged over 18?

Would you like to participate in a Clinical Research Study of a new treatment for CML?

If you would like further information please contact:

Prof Richard Clark
tel. 0151 706 4344
email: R.E.Clark@liverpool.ac.uk

Background information on this trial:

ENESTnd is a phase III randomized, open-label, multicenter study comparing the efficacy and safety of nilotinib versus Glivec®/Gleevec®* (imatinib) in adult patients with newly diagnosed Ph+ CML in the chronic phase.


Patients will be randomized to nilotinib 400 mg BID, nilotinib 300 mg BID, or *Glivec/Gleevec 400 mg QD. ENESTnd will be open in 220 global sites.



*Glivec is the trade name for imatinib outside the United States and Gleevec is the trade name for imatinib mesylate in the United States.




....Click here to learn more about this study from Clinicaltrials.gov